The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L04 | Immunosuppressants | |
3
|
L04A | Immunosuppressants | |
4
|
L04AJ | Complement inhibitors | |
5
|
L04AJ08 |
| Active Ingredient |
|---|
|
Iptacopan is a proximal complement inhibitor that targets Factor B (FB) to selectively inhibit the alternative pathway. In paroxysmal nocturnal haemoglobinuria (PNH), inhibition of FB in the alternative pathway of the complement cascade prevents the activation of C3 convertase and the subsequent formation of C5 convertase to control both C3-mediated extravascular haemolysis (EVH) and terminal complement-mediated intravascular haemolysis (IVH). In C3G, overactivation of the complement alternative pathway leads to deposition of C3 within the glomeruli, triggering inflammation, glomerular injury, and kidney fibrosis. Iptacopan selectively blocks the alternative pathway overactivation by inhibiting the alternative pathway related C3 convertase activity, leading to decreased cleavage of C3 and reduced C3 deposition in the kidney. |
| Document | Type | Information Source | |
|---|---|---|---|
| FABHALTA Hard capsule | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| FABHALTA Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.